红细胞比容预测肺癌患者化疗耐受性的初步探讨  

Preliminary Study of Hematocrit in Predicting Chemotherapy Tolerance in Patients with Lung Cancer

作　　者：王雪雁[1] 曹德生[1] 罗迪[1] WANG Xue-yan;CAO De-sheng;LUO Di(Department of Clinical Laboratory, Dalian Second People's Hospital, Dalian 116011, China)

机构地区：[1]大连市第二人民医院检验科

出　　处：《中国医药指南》2019年第18期20-21,共2页Guide of China Medicine

摘　　要：目的探讨红细胞比容预测肺癌患者化疗耐受性情况。方法选取2017年1月至2018年1月在大连市第二人民医院就诊200例肺癌化疗患者,根据疾病小细胞癌的不同分期,分为Ⅰ~Ⅱ组100例和Ⅲ~Ⅳ组100例,比较两组患者红细胞比容(HCT)、红细胞平均容积(MCV)、红细胞平均血红蛋白含量(MCH)、红细胞血红蛋白浓度(MCHC)、红细胞分布宽度(RDW)等。结果Ⅲ~Ⅳ组观察指标阳性率>Ⅰ~Ⅱ组阳性率,差异有统计学意义(P<0.05)。结论肺癌患者更具疾病的分期不同,其化疗后红细胞比容阳性率有差异,红细胞比容对化疗耐受成都的判断有一定的意义。Objective To investigate the chemotherapy tolerance of patients with lung cancer in patients with lung cancer. Methods From January 2017 to January 2018 in dalian second people’s hospital clinical laboratory, 200 cases of lung cancer chemotherapy patients, according to different stages of non-small cell carcinoma of the diseases, divided into Ⅰ-Ⅱ group Ⅲ-Ⅳ group 100 cases and 100 cases, compared two groups of patients’ erythrocyte deposited(HCT),average red blood cell volume(MCV), red blood hemoglobin content(MCH), red blood cell hemoglobin concentration(MCHC), red blood cell distribution width(RDW) and the like. Results The positive rate of observation index in Ⅲ-Ⅳ group >Ⅰ-Ⅱ group was statistically significant(P <0.05).. Conclusion Patients with lung cancer have different stages of disease, and there is a difference in the positive rate of erythrocyte pressure after chemotherapy.

关 键 词：红细胞比容 肺癌 化疗耐受性 

分 类 号：R734.2[医药卫生—肿瘤]